Your browser doesn't support javascript.
loading
HIV-1 envelope gp41 antibodies can originate from terminal ileum B cells that share cross-reactivity with commensal bacteria.
Trama, Ashley M; Moody, M Anthony; Alam, S Munir; Jaeger, Frederick H; Lockwood, Bradley; Parks, Robert; Lloyd, Krissey E; Stolarchuk, Christina; Scearce, Richard; Foulger, Andrew; Marshall, Dawn J; Whitesides, John F; Jeffries, Thomas L; Wiehe, Kevin; Morris, Lynn; Lambson, Bronwen; Soderberg, Kelly; Hwang, Kwan-Ki; Tomaras, Georgia D; Vandergrift, Nathan; Jackson, Katherine J L; Roskin, Krishna M; Boyd, Scott D; Kepler, Thomas B; Liao, Hua-Xin; Haynes, Barton F.
Affiliation
  • Trama AM; Duke Human Vaccine Institute, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA; Department of Immunology, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA. Electronic address: ashley.trama@dm.duke.edu.
  • Moody MA; Duke Human Vaccine Institute, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA; Department of Pediatrics, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA.
  • Alam SM; Duke Human Vaccine Institute, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA.
  • Jaeger FH; Duke Human Vaccine Institute, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA.
  • Lockwood B; Duke Human Vaccine Institute, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA.
  • Parks R; Duke Human Vaccine Institute, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA.
  • Lloyd KE; Duke Human Vaccine Institute, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA.
  • Stolarchuk C; Duke Human Vaccine Institute, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA.
  • Scearce R; Duke Human Vaccine Institute, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA.
  • Foulger A; Duke Human Vaccine Institute, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA.
  • Marshall DJ; Duke Human Vaccine Institute, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA.
  • Whitesides JF; Duke Human Vaccine Institute, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA.
  • Jeffries TL; Duke Human Vaccine Institute, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA.
  • Wiehe K; Duke Human Vaccine Institute, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA.
  • Morris L; Centre for HIV and STIs, National Institute for Communicable Diseases, Johannesburg 2131, South Africa.
  • Lambson B; Centre for HIV and STIs, National Institute for Communicable Diseases, Johannesburg 2131, South Africa.
  • Soderberg K; Duke Human Vaccine Institute, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA.
  • Hwang KK; Duke Human Vaccine Institute, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA.
  • Tomaras GD; Duke Human Vaccine Institute, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA; Department of Surgery, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA; Department of Molecular Genetics and Microbiology, Duke Univers
  • Vandergrift N; Duke Human Vaccine Institute, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA.
  • Jackson KJL; Department of Pathology, Stanford University, Palo Alto, CA 94305, USA.
  • Roskin KM; Department of Pathology, Stanford University, Palo Alto, CA 94305, USA.
  • Boyd SD; Department of Pathology, Stanford University, Palo Alto, CA 94305, USA.
  • Kepler TB; Department of Microbiology, Boston University, Boston, MA 02215, USA.
  • Liao HX; Duke Human Vaccine Institute, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA.
  • Haynes BF; Duke Human Vaccine Institute, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA; Department of Immunology, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine a
Cell Host Microbe ; 16(2): 215-226, 2014 Aug 13.
Article in En | MEDLINE | ID: mdl-25121750
ABSTRACT
Monoclonal antibodies derived from blood plasma cells of acute HIV-1-infected individuals are predominantly targeted to the HIV Env gp41 and cross-reactive with commensal bacteria. To understand this phenomenon, we examined anti-HIV responses in ileum B cells using recombinant antibody technology and probed their relationship to commensal bacteria. The dominant ileum B cell response was to Env gp41. Remarkably, a majority (82%) of the ileum anti-gp41 antibodies cross-reacted with commensal bacteria, and of those, 43% showed non-HIV-1 antigen polyreactivity. Pyrosequencing revealed shared HIV-1 antibody clonal lineages between ileum and blood. Mutated immunoglobulin G antibodies cross-reactive with both Env gp41 and microbiota could also be isolated from the ileum of HIV-1 uninfected individuals. Thus, the gp41 commensal bacterial antigen cross-reactive antibodies originate in the intestine, and the gp41 Env response in HIV-1 infection can be derived from a preinfection memory B cell pool triggered by commensal bacteria that cross-react with Env.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: HIV Antibodies / HIV Envelope Protein gp41 / HIV Infections / HIV-1 / Microbiota / Ileum Limits: Humans Language: En Journal: Cell Host Microbe Journal subject: MICROBIOLOGIA Year: 2014 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: HIV Antibodies / HIV Envelope Protein gp41 / HIV Infections / HIV-1 / Microbiota / Ileum Limits: Humans Language: En Journal: Cell Host Microbe Journal subject: MICROBIOLOGIA Year: 2014 Document type: Article